Drug resistance and tuberculosis elimination in low-incidence countries

European Respiratory Journal

Volumn 44, Issue 6, 2014, Pages 1408-1411

  Falzon, Dennis ^a   Zellweger, Jean Pierre ^b   Migliori, Giovanni Battista ^a   Jaramillo, Ernesto ^a  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

^b Swiss Lung Association   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ISONIAZID; QUINOLONE DERIVATIVE; RIFAMPICIN; TUBERCULOSTATIC AGENT;

ANTIBIOTIC RESISTANCE; AUSTRIA; AWARENESS; BACTERIAL LOAD; BACTERIAL STRAIN; BAHAMAS; BELGIUM; CANADA; CLINICAL EFFECTIVENESS; COSTA RICA; CUBA; DISEASE COURSE; DRUG SAFETY; EPIDEMIC; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; GERMANY; HEALTH CARE COST; HEALTH SERVICE; HELP SEEKING BEHAVIOR; HUMAN; INCIDENCE; INFECTION CONTROL; INFECTION RISK; IRELAND; ISRAEL; JAMAICA; JORDAN; MULTIDRUG RESISTANT TUBERCULOSIS; NETHERLANDS; NEW ZEALAND; NORWAY; PRACTICE GUIDELINE; PUERTO RICO; REVIEW; RISK FACTOR; SLOVAKIA; SWEDEN; TREATMENT DURATION; TREATMENT PLANNING; TUBERCULOSIS; TUBERCULOSIS CONTROL; UNITED ARAB EMIRATES; UNITED STATES; DISEASE ERADICATION; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY;

ANTITUBERCULAR AGENTS; DISEASE ERADICATION; DRUG RESISTANCE, BACTERIAL; HUMANS; INCIDENCE; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY;

EID: 84916236529     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00138014     Document Type: Review

References (38)

1. Clancy L, Rieder HL, Enarson DA, et al. Tuberculosis elimination in the countries of Europe and other industrialized countries. Eur Respir J 1991; 4: 1288-1295.
2. Lönnroth K, Migliori GB, Raviglione M. Towards tuberculosis elimination in low-incidence countries -reflections from a global consultation. Ann Intern Med 2014 [In press].
3. Story A, Murad S, Roberts W, et al. Tuberculosis in London: the importance of homelessness, problem drug use and prison. Thorax 2007; 62: 667-671.
4. Borgdorff MW, van den Hof S, Kremer K, et al. Progress towards tuberculosis elimination: secular trend, immigration and transmission. Eur Respir J 2010; 36: 339-347.
5. Resolution WHA62.15. Prevention and control of multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis. In: WHO, Sixty-second World Health Assembly, Geneva, 18-22 May 2009, Resolutions and decisions; annexes. Geneva, WHO, 2009; pp. 25-29.
6. Devaux I, Kremer K, Heersma H, et al. Clusters of multidrug-resistant Mycobacterium tuberculosis cases, Europe. Emerging Infect Dis 2009; 15: 1052-1060.
7. Quitugua TN, Seaworth BJ, Weis SE, et al. Transmission of drug-resistant tuberculosis in Texas and Mexico. J Clin Microbiol 2002; 40: 2716-2724.
8. European Centre for Disease Prevention and Control, WHO Regional Office for Europe. Tuberculosis surveillance and monitoring in Europe 2014. Stockholm, ECDC, 2014.
9. Falzon D, Infuso A, Aït-Belghiti F. In the European Union, TB patients from former Soviet countries have a high risk of multidrug resistance. Int J Tuberc Lung Dis 2006; 10: 954-958.
10. World Health Assembly. Resolution WHA67.1. Global strategy and targets for tuberculosis prevention, care and control after 2015. http://apps.who.int/gb/ebwha/pdf-files/WHA67/A67-R1-en.pdf
11. Van der Werf MJ, Langendam MW, Huitric E, et al. Multidrug resistance after inappropriate tuberculosis treatment: a meta-analysis. Eur Respir J 2012; 39: 1511-1519.
12. Lanzieri G. Fewer, older and multicultural? Projections of the EU populations by foreign/national background http://epp.eurostat.ec.europa.eu/cache/ITY-OFFPUB/KS-RA-11-019/EN/KS-RA-11-019-EN.PDF
13. US Census Bureau. International Migration is Projected to Become Primary Driver of U.S. Population Growth for First Time in Nearly Two Centuries. www.census.gov/newsroom/releases/archives/population/cb13-89.html Date last accessed: July 7, 2014. Date last updated: May 15, 2013.
14. Coleman D. The impact of immigration on the populations of the developed world and their ethnic composition. http://gt2030.com/2012/08/03/the-impact-of-immigration-on-the-populations-of-the-developed-world-and-theirethnic-composition/Date last accessed: July 7, 2014.
15. Dye C, Williams BG, Espinal MA, et al. Erasing the world's slow stain: strategies to beat multidrug-resistant tuberculosis. Science 2002; 295: 2042-2046.
16. Ahuja SD, Ashkin D, Avendano M, et al. Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients. PLoS Med 2012; 9: e1001300.
17. Diel R, Vandeputte J, de Vries G, et al. Costs of tuberculosis disease in the European Union: a systematic analysis and cost calculation. Eur Respir J 2014; 43: 554-565.
18. Loddenkemper R, Sotgiu G, Mitnick CD. Cost of tuberculosis in the era of multidrug resistance: will it become unaffordable? Eur Respir J 2012; 40: 9-11.
19. World Health Organization. Tuberculosis (TB). www.who.int/tb/country/en
20. Centers for Disease Control and Prevention. Tuberculosis morbidity -United States, 1992. MMWR Morb Mortal Wkly Rep 1993; 42: 696-697.
21. Frieden TR, Fujiwara PI, Washko RM, et al. Tuberculosis in New York City -turning the Tide. N Engl J Med 1995; 333: 229-233.
22. Falzon D, Zignol M, Migliori GB, et al. Migration: an opportunity for the improved management of tuberculosis worldwide. Ital J Public Health 2012; 9: e7524.
23. Dara M, de Colombani P, Petrova-Benedict R, et al. The minimum package for cross-border TB control and care in the WHO European region: a Wolfheze consensus statement. Eur Respir J 2012; 40: 1081-1090.
24. Royce S, Falzon D, van Weezenbeek C, et al. Multidrug resistance in new tuberculosis patients: burden and implications. Int J Tuberc Lung Dis 2013; 17: 511-513.
25. Otero L, Krapp F, Tomatis C, et al. High prevalence of primary multidrug resistant tuberculosis in persons with no known risk factors. PLoS One 2011; 6: e26276.
26. Schwartzman K, Oxlade O, Barr RG, et al. Domestic returns from investment in the control of tuberculosis in other countries. N Engl J Med 2005; 353: 1008-1020.
27. Migliori GB, Sotgiu G, Gandhi NR, et al. Drug resistance beyond extensively drug-resistant tuberculosis: individual patient data meta-analysis. Eur Respir J 2013; 42: 169-179.
28. World Health Organization. Global tuberculosis report 2014 (WHO/HTM/TB/2014.08). Geneva, WHO, 2014.
29. Falzon D, Gandhi N, Migliori GB, et al. Resistance to fluoroquinolones and second-line injectable drugs: impact on MDR-TB outcomes. Eur Respir J 2013; 42: 156-168.
30. Migliori GB, De Iaco G, Besozzi G, et al. First tuberculosis cases in Italy resistant to all tested drugs. Euro Surveill 2007; 12: E070517.1.
31. Murase Y, Maeda S, Yamada H, et al. Clonal expansion of multidrug-resistant and extensively drug-resistant tuberculosis, Japan. Emerg Infect Dis 2010; 16: 948-954.
32. World Health Organization. Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis. (WHO/HTM/TB/2014.11). Geneva, WHO, 2014.
33. Toczek A, Cox H, du Cros P, et al. Strategies for reducing treatment default in drug-resistant tuberculosis: systematic review and meta-analysis. Int J Tuberc Lung Dis 2013; 17: 299-307.
34. Uffredi ML, Truffot-Pernot C, Dautzenberg B, et al. An intervention programme for the management of multidrug-resistant tuberculosis in France. Int J Antimicrob Agents 2007; 29: 434-439.
35. Blasi F, Dara M, Werf MJ, et al. Supporting TB clinicians managing difficult cases: the ERS/WHO Consilium. Eur Respir J 2013; 41: 491-494.
36. World Health Organization. A practical handbook on the pharmacovigilance of medicines used in the treatment of tuberculosis: enhancing the safety of the TB patient. www.who.int/medicines/publications/Pharmaco-TB-web-v3.pdf
37. World Health Organization. The use of bedaquiline in the treatment of multidrug-resistant tuberculosis. Interim policy guidance (WHO/HTM/TB/2013.6). http://apps.who.int/iris/bitstream/10665/84879/1/9789241505482-eng.pdf
38. Weyer K, Mirzayev F, Migliori GB, et al. Rapid molecular TB diagnosis: evidence, policy-making and global implementation of Xpert MTB/RIF. Eur Respir J 2013; 42: 252-271.